Free Trial

Krystal Biotech (KRYS) Earnings Date, Estimates & Call Transcripts

Krystal Biotech logo
$164.83 +4.00 (+2.49%)
(As of 12/20/2024 05:16 PM ET)

Krystal Biotech Latest Earnings Summary

Actual EPS
(Nov. 4)
$0.91 Beat By $0.07
Consensus EPS
(Nov. 4)
$0.84

Krystal Biotech released Q3 2024 earnings on November 4, 2024, reporting an EPS of $0.91, which beat analysts' consensus estimates of $0.84 by $0.07. Quarterly revenue rose 879.9% year-over-year to $83.84 million, above analyst estimates of $82.94 million. With a trailing EPS of $1.77 and a P/E Ratio of 93.12, Krystal Biotech's earnings are expected to grow 100.34% next year, from $2.97 to $5.95 per share.

Get Krystal Biotech Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Krystal Biotech and other key companies, straight to your inbox.

Sign Up
Skip Charts & View Estimated and Actual Earnings Data

KRYS Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

KRYS Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Krystal Biotech Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20242$0.08$0.30$0.19
Q2 20242$0.37$0.67$0.52
Q3 20242$0.89$1.02$0.96
Q4 20242$1.15$1.81$1.48
FY 20248$2.49$3.80$3.15
Q1 20251$1.43$1.43$1.43
Q2 20251$1.59$1.59$1.59
Q3 20251$1.61$1.61$1.61
Q4 20251$1.50$1.50$1.50
FY 20254$6.13$6.13$6.13

Krystal Biotech Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails
11/4/2024Q3 2024$0.84$0.91+$0.07$0.91$82.94M$83.84M
8/5/2024Q2 2024$0.50$0.53+$0.03$1.19$65.27M$70.28M
5/6/2024Q1 2024$0.20$0.03 -$0.17$0.03$47.37M$45.25M
2/26/2024Q4 2023-$0.52$0.30+$0.82$0.30$27.43M$42.14M
11/6/2023Q3 2023-$1.10$2.79+$3.89-$4.13$6.29M$8.60M
8/7/2023Q2 2023-$1.27-$1.25+$0.02-$1.25--
5/8/2023Q1 2023-$1.41-$1.76 -$0.35-$1.76--
2/27/2023Q4 2022-$1.26-$1.25+$0.01-$1.25--

Krystal Biotech Earnings - Frequently Asked Questions

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earning data on Monday, November 4, 2024. Learn more on KRYS's earnings history.

In the previous quarter, Krystal Biotech (NASDAQ:KRYS) reported $0.91 earnings per share (EPS) to beat the analysts' consensus estimate of $0.84 by $0.07. Learn more on analysts' earnings estimate vs. KRYS's actual earnings.

The conference call for Krystal Biotech's latest earnings report can be listened to online.
Listen to Conference Call

The conference call transcript for Krystal Biotech's latest earnings report can be read online.
Read Transcript

Krystal Biotech's earnings report can be found in their filing with the SEC.
View SEC filing

Krystal Biotech (NASDAQ:KRYS) has a recorded annual revenue of $241.52 million.

Krystal Biotech (NASDAQ:KRYS) has a recorded net income of $10.93 million. KRYS has generated $1.77 earnings per share over the last four quarters.

Krystal Biotech (NASDAQ:KRYS) has a trailing price-to-earnings ratio of 93.12 and a forward price-to-earnings ratio of 55.50.

Krystal Biotech's earnings are expected to grow from $2.97 per share to $5.95 per share in the next year, which is a 100.34% increase.

More Earnings Resources from MarketBeat



This page (NASDAQ:KRYS) was last updated on 12/21/2024 by MarketBeat.com Staff
From Our Partners